On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serves as the core infrastructure for “agentic commercial,” Veeva’s AI-driven commercial framework designed to modernize field engagement and speed medicine delivery. While Veeva serves as the tech engine driving efficiency in life sciences, Eli Lilly stands as the pharmaceutical titan creating those therapies. Both occupy distinct sectors, enterprise software versus biopharmaceuticals, yet their expanding partnership highlights how technology and drug development are becoming deeply intertwined.
Financial Health and Sector Dynamics
Since Veeva Systems Inc. (NYSE:VEEV) is a vertical SaaS vendor and Eli Lilly and Company (NYSE:LLY) is a pharmaceutical manufacturer, direct financial comparison must account for their unique models. Enterprise tech relies on recurring subscriptions and high operating leverage, whereas biopharma depends on clinical trial velocity, manufacturing scale, and global regulatory approvals.
In its Fiscal 2027 First Quarter (ended April 30, 2026), Veeva delivered total revenue of $882.9 million, up 16% year-over-year, driven by $730.2 million in subscription revenue (up 15%). Non-GAAP EBIT reached $395 million, yielding an impressive operating margin above 44%.
Eli Lilly demonstrated remarkable top-line acceleration in Q2 2026. Revenue surged 48% year-over-year to $22.97 billion, propelled by explosive volume demand for GLP-1 therapies Mounjaro and Zepbound. Non-GAAP net income rose 32% to $7.49 billion ($8.38 per share). Lilly raised its full-year 2026 revenue guidance to $85.0–$87.0 billion, underscoring its operational momentum despite absorbing $3.03 per share in acquired R&D charges. On August 7, Truist raised its price target on LLY to $1,376 from $1,370 with a Buy rating, citing substantial incretin volume growth offsetting pricing pressure.
Key Drivers and Catalyst Pipeline
LLY’s momentum extends well beyond commercial execution into regulatory breakthroughs. On August 10, the UK’s MHRA authorized Foundayo (orforglipron), making Britain the first European country to approve Lilly’s once-daily oral GLP-1 pill for weight management and type 2 diabetes. Unlike existing oral options, Foundayo carries no food or water restrictions, positioning it as a major catalyst to expand treatment access globally.
Insider Monkey’s Hedge Fund Data Analysis
The latest Insider Monkey hedge fund tracking data points to a modest decline in institutional participation across both equities in Q1 2026. Veeva Systems Inc. (NYSE:VEEV) was held by 62 hedge funds, down from 75 in Q4 2025. Among its major holders, Zevenbergen Capital Investments, led by Nancy Zevenbergen, held 111,527 shares valued at approximately $19.8 million, reflecting a 5% decline in activity. Meanwhile, Long Path Partners, led by William Brennan and Brian Nelson, held 52,738 shares worth about $9.4 million, representing a 61% increase in activity.
Eli Lilly and Company (NYSE:LLY) was held by 132 hedge funds in Q1 2026, slightly below the 137 funds reported in Q4 2025. Fisher Asset Management, led by Ken Fisher, remained a major holder with 5,063,516 shares valued at approximately $6.07 billion, and activity increased by 5%. Locust Wood Capital Advisers, led by Stephen J. Errico, held 39,718 shares worth about $47.6 million, while increasing its activity by 95%.
Conclusion: What Investors Should Watch Next
Both companies demonstrate strong fundamentals within their respective industries. Veeva offers steady, high-margin SaaS growth anchored by sticky enterprise adoption, while Eli Lilly provides high-velocity growth driven by mega-blockbuster GLP-1 therapies. Investors should watch Veeva’s pace of global Vault CRM rollouts across major pharma accounts and the monetization of its AI Falcon platform. For Eli Lilly, key catalysts include the commercial rollout of Foundayo following its UK approval and international regulatory decisions.
While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
